Recent Updates
Recently added Catalysts
SRPT Negative Sentiment Score: 25/100

Sarepta Therapeutics, Inc. Sued for Securities Law Violations – Investors Should Contact The Gross Law Firm for More Information – SRPT

Key Takeaway: Sarepta Therapeutics, Inc. is currently facing a lawsuit alleging securities law violations related to its gene therapy product ELEVIDYS. The allegations claim that the company issued false and misleading statements regarding the safety of the therapy and its trial results. These issues reportedly led to significant adverse events that necessitated halting recruitment and dosing in clinical trials. Shareholders are being urged to register for potential recovery as lead plaintiffs before the August 25, 2025 deadline.

Market Sentiment Analysis

CONCERNS & RISKS

  • Sarepta Therapeutics is facing a lawsuit for securities law violations.
  • The complaint includes allegations of misleading statements about the gene therapy ELEVIDYS.
  • The therapy posed significant safety risks, leading to a halt in patient recruitment and dosing.
  • Investors could face potential losses due to the negative impact of the lawsuit on stock value.

Full Press Release Details

NEW YORK, Aug. 21, 2025 (GLOBE NEWSWIRE) -- The Gross Law Firm issues the following notice to shareholders of Sarepta Therapeutics, Inc. (NASDAQ: SRPT).
Shareholders who purchased shares of SRPT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.
CLASS PERIOD: June 22, 2023 to June 24, 2025
ALLEGATIONS: The complaint alleges that during the class period, Defendants issued materially false and/or misleading statements and/or failed to disclose that: (i) ELEVIDYS, a prescription gene therapy for Duchenne, posed significant safety risks to patients; (ii) ELEVIDYS trial regimes and protocols failed to detect severe side effects; (iii) the severity of adverse events from ELEVIDYS treatment would cause the Company to halt recruitment and dosing in ELEVIDYS trials, attract regulatory scrutiny, and create greater risk around the therapy’s present and expanded approvals; and (iv) as a result of the foregoing, defendants materially misled with, and/or lacked a reasonable basis for, their positive statements.
DEADLINE: August 25, 2025 Shareholders should not delay in registering for this class action. Register your information here: https://securitiesclasslaw.com/securities/sarepta-loss-submission-form/?id=162511&from=3
NEXT STEPS FOR SHAREHOLDERS: Once you register as a shareholder who purchased shares of SRPT during the timeframe listed above, you will be enrolled in a portfolio monitoring software to provide you with status updates throughout the lifecycle of the case. The deadline to seek to be a lead plaintiff is August 25, 2025. There is no cost or obligation to you to participate in this case.
WHY GROSS LAW FIRM? The Gross Law Firm is a nationally recognized class action law firm, and our mission is to protect the rights of all investors who have suffered as a result of deceit, fraud, and illegal business practices. The Gross Law Firm is committed to ensuring that companies adhere to responsible business practices and engage in good corporate citizenship. The firm seeks recovery on behalf of investors who incurred losses when false and/or misleading statements or the omission of material information by a company lead to artificial inflation of the company's stock. Attorney advertising. Prior results do not guarantee similar outcomes.
15 West 38th Street, 12th floor
Phone: (646) 453-8903

Tags

Frequently Asked Questions

What is the class period for Sarepta Therapeutics?

The class period for Sarepta Therapeutics is from June 22, 2023, to June 24, 2025.

What are the allegations against Sarepta Therapeutics?

The allegations include misleading statements about ELEVIDYS's safety risks and trial protocols.

What is the deadline to register for the class action?

Shareholders must register by August 25, 2025, to participate in the class action.

Do I need to be a lead plaintiff to recover losses?

No, you do not need to be a lead plaintiff to receive any recovery.

How can I monitor the status of the case?

Once registered, shareholders will receive updates through a portfolio monitoring software.

Last updated: Aug 21, 2025